Concepedia

Phase II study of the farnesyl transferase inhibitor R115777 in patients with sensitive relapse small-cell lung cancer

John V. Heymach, David H. Johnson, Fadlo R. Khuri, Howard Safran, Larry Schlabach, F. Yunus, R.F. DeVore, Peter M. De Porre, Henry Richards, Xiaoyu Jia,

Annals of Oncology · 2004 · 89 citations · 31 references

DOIFull text

Open access

Concepts

References

31

Reporting results of cancer treatment

A. B. Miller, Barth Hoogstraten, M. Staquet et al. · Cancer · 1981 · 7.8K citations

, , +13

Topotecan Versus Cyclophosphamide, Doxorubicin, and Vincristine for the Treatment of Recurrent Small-Cell Lung Cancer

Joachim von Pawel, Joan H. Schiller, Frances A. Shepherd et al. · Journal of Clinical Oncology · 1999 · 943 citations

Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group.

Andrea Ardizzoni, H. Hansen, P Dombernowsky et al. · Journal of Clinical Oncology · 1997 · 479 citations

BindingDB Entry 2025: Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro.

PubMed · 2007 · 462 citations · Full text

Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial

Judith E. Karp, Jeffrey E. Lancet, Scott H. Kaufmann et al. · Blood · 2001 · 445 citations · Full text